Presentation will detail impact of Cortexyme’s lead compound, COR388, on ApoE in Alzheimer’s Disease patients

– CTAD attendees are also invited to educational session focused on Cortexyme’s new investigational approach to AD treatment

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Nov. 1, 2019– Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel, disease-modifying therapeutic approach to treat what it believes to be a key underlying cause of Alzheimer’s and other degenerative diseases, today announced that its lead investigational medicine, COR388, will be the subject of an oral presentation at Clinical Trials on Alzheimer’s Disease (CTAD) 2019. The company will also host a lunch briefing on the preclinical and clinical data supporting COR388’s mechanism of action, as well as its evaluation in the ongoing Phase 2/3 GAIN trial. CTAD brings together leaders in Alzheimer’s Disease (AD) research and treatment to discuss new results, potential new therapeutics and methodological issues involved in the development of AD therapies, and will take place from December 4-7, 2019 in San Diego.

“As an industry, we are seeing the conversation around Alzheimer’s research move towards new, innovative approaches to treatment which act upstream of Alzheimer’s pathology,” said Casey Lynch, Cortexyme’s chief executive officer, chair, and co-founder. “We’re looking forward to advancing that conversation at this year’s CTAD conference. With both our oral presentation on Saturday and our lunch briefing on Thursday, we hope to provide the community with additional evidence behind the gingipain hypothesis, including the downstream effects on genetic risk factors, abeta, inflammation and neurodegeneration.”

Michael Detke, M.D., Ph.D., Cortexyme’s chief medical officer, will lead the oral presentation. The presentation, abstract OC28, is entitled, “COR388, A Novel Gingipain Inhibitor, Decreases Fragmentation of ApoE in Alzheimer’s Disease Central Nervous System,” and will take place on Saturday, December 7, at 10:00 a.m. local time.

The lunch briefing, “P. gingivalis in Alzheimer’s Disease Brains: Evidence for Disease Causation and Treatment with COR388,” will be open to all CTAD attendees, and will take place on Thursday, December 5, from 12:30-1:30 p.m. in Room Sapphire E/F. Attendees will have an opportunity to learn more about how Cortexyme is targeting a potential root cause of AD, including background on the ongoing Phase 2/3 GAIN Trial and the data supporting the gingipain hypothesis, as well as Phase 1 a/b biomarker and cognitive data. The GAIN Trial, investigating Cortexyme’s lead compound COR388, is based on a growing body of evidence supporting a key role for Porphyromonas gingivalis, the bacterium most commonly associated with chronic periodontal disease, and its proteolytic gingipains in the development of AD.

For more information about CTAD 2019, including a full schedule of presentations, visit the conference website. To secure your reservation for Cortexyme’s lunch briefing, please register on the event page.

About the GAIN Trial

The GAIN Trial is a Phase 2/3 randomized, double-blind, placebo-controlled study assessing the efficacy, safety, and tolerability of two dose levels of COR388 oral capsules in subjects with mild to moderate AD. The trial is currently enrolling subjects in the U.S. and Europe, and top-line results from the trial are anticipated in the fourth quarter of 2021. More information about the trial can be found at

About Cortexyme, Inc.

Cortexyme (Nasdaq: CRTX) is a clinical stage biopharmaceutical company pioneering a novel, disease-modifying therapeutic approach to treat what it believes to be a key underlying cause of Alzheimer’s disease and other degenerative diseases. Cortexyme is targeting a specific, infectious pathogen found in the brain of Alzheimer’s patients and tied to neurodegeneration and neuroinflammation in animal models. The company’s lead investigational medicine, COR388, is the subject of the GAIN Trial, an ongoing Phase 2/3 clinical study in patients with mild to moderate Alzheimer’s. To learn more about Cortexyme, visit or follow @Cortexyme on Twitter.

Forward-Looking Statements

Statements in this press release contain “forward-looking statements” that are subject to substantial risks and uncertainties. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “expect,” “believe,” “will,” “may,” “should,” “estimate,” “project,” “outlook,” “forecast” or other similar words. Forward-looking statements are based on Cortexyme’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, but are not limited to, the risks and uncertainties described in the section titled “Risk Factors” in the final prospectus related to Cortexyme’s initial public offering filed with the Securities and Exchange Commission on May 9, 2019 and Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on June 12, 2019. Forward-looking statements contained in this press release are made as of this date, and Cortexyme undertakes no duty to update such information except as required under applicable law.

Source: Cortexyme, Inc.

Hal Mackins
For Cortexyme
(415) 994-0040